Fig. 1From: New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their managementImmune checkpoints: physiological function and mode of action of inhibiting monoclonal antibodies (checkpoint inhibitors). CTLA-4 cytotoxic T-lymphocyte-associated protein 4, PD-1 programmed death receptor 1, PD-L1 ligand of PD-1, CPI checkpoint inhibitor(s), APC antigen-presenting cell, MHC major histocompatibility complex, TCR T-cell receptorBack to article page